Last reviewed · How we verify
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads
This pilot clinical trial compares the use of contrast-enhanced ultrasound to contrast-enhanced magnetic response imaging (MRI), the current clinical standard, in predicting treatment response in patients with liver cancer receiving transarterial chemoembolization with drug eluting beads. Comparing results of diagnostic procedures before and after transarterial chemoembolization may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known if contrast-enhanced ultrasound works better than contrast-enhanced MRI in predicting treatment response in patients with liver cancer.
Details
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 15 |
| Start date | Wed Dec 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Dec 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hepatocellular Carcinoma
Interventions
- Perflutren Lipid Microspheres
- Dynamic Contrast-Enhanced Ultrasound Imaging
- Contrast-enhanced Magnetic Resonance Imaging